# Anti-VEGF Therapy Versus Dexamethasone Implant for DME

> **NCT03999125** · PHASE4 · UNKNOWN · sponsor: **Sudhalkar Eye Hospital** · enrollment: 150 (estimated)

## Conditions studied

- Clinically Significant Macular Edema Due to Diabetes Mellitus

## Interventions

- **DRUG:** Aflibercept,
- **DRUG:** Ranibizumab Injection
- **DRUG:** Ozurdex Drug Implant Product

## Key facts

- **NCT ID:** NCT03999125
- **Lead sponsor:** Sudhalkar Eye Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-25
- **Primary completion:** 2021-06-24
- **Final completion:** 2023-06-24
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2019-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03999125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03999125, "Anti-VEGF Therapy Versus Dexamethasone Implant for DME". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03999125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*